2012-11-27 08:19:31 -
According to a published Bloomberg First Word survey, which sought the opinions
of physicians and four analysts, the medullary thyroid cancer candidate
Cabozantinib from Exelixis, Inc. (NASDAQ: EXEL) which faces an FDA PDUFA
decision date on November 29th is likely to get approved.
Formerly known as XL184, Cabozantinib, is said to work by blocking signaling
that leads to cancer growth as well as blocking the growth of new blood vessels
(angiogenesis) that help to feed a tumor. After approval, the drug could be used
"off-label" to treat other cancers.
Analysts from four large firms who have been following the story list the odds
for Cabozantinib's approval as follows:
* Lazard at 75 percent to 85 percent
* Piper Jaffray at 80 percent
* Jefferies at 80
* Cowen at 70 percent
Published reports have Holtorf Medical Group's Dr. Kent Holtorf stating that the
clinical data looked "very reassuring" and more promising for patients than any
other alternatives. He notes that it will be exciting for physician's, which
will now be able to offer something to patients upon approval.
While Piper Jaffray's Ed Tenthoff warns that investors might try to sell the
news following the FDA decision this week, Lazard's Biren Amin sees Exelixis at
$6 to $7 upon approval, or $4 to $5 if rejected.
Exelixis shares traded mostly sideways during today's mixed market, but have
seen a surge in recent weeks leading up to this decision.
The full report about how traders are bracing for the upcoming decision is
Healthcare investors and Biotech traders interested in accessing BioMedReports'
new complete database of clinical trials and upcoming FDA and world-wide
regulatory decisions which can be used to make more profitable trades and see
upcoming catalysts can go to: biomedreports.com/fdacal.html
News developments and live healthcare sector updates are available constantly
via twitter at: twitter.com/BioMedReports
BioMedReports is a news and research portal covering financial biotech news for
the entire Healthcare Sector of the market. BioMedReports is not paid or
compensated to report the news and developments of publicly traded companies.
BioMedReports sells a premium product for subscribers and full disclosures and
information about the stocks and news mentioned in this news release are
available at BioMedReports.Com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: BioMedReports via Thomson Reuters ONE